Bottles with blue caps

Product Pipeline

Focused on Innovation

CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant protein technology, cell and gene therapy and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunoglobulins, Hematology, Cardiovascular & Renal, Immunology and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.

Core Capabilities

as demonstrated in our product pipeline 

Phase II

Phase III

Registration / Post Registration

CSL R&D Portfolio – FY27
Phase II

CSL787 Nebulised Ig

Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).

Anumigilimab Anti-G-CSFR mAb (SCD prophylaxis)

An anti-G-CSFR recombinant monoclonal antibody for prophylactic use in Sickle Cell Disease to reduce the incidence of vaso-occlusive crises

Hemopexin (VOC in SCD)

Plasma-derived hemopexin for potential treatment of acute Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients.

Vamifeport Ferroportin Inhibitor (HH)

Oral Ferroportin Inhibitor (small molecule) for treatment of iron overload in hereditary hemochromatosis

CSL 301 Anti-α2AP mAb (sPE)*

Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).

CSL404 Cell-based Pandemic Influenza (H5N8) Vaccine

For protection against pandemic influenza A (H5N8) virus strain

Phase III

HIZENTRA® (SCIg) 20% Liquid (SID)

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Secondary Immunodeficiency (SID) as a result of Chronic Lymphocytic Lukemia (CLL)

HIZENTRA® (SCIg) 20% Liquid (PID Naïve)

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Primary Immunodeficiency (PID) for patients without prior IVIg treatments

Horizon 2 Ig Yield

Using novel technologies to optimise processes for increased Ig yield

KCENTRA® PCC (Surgical Bleeding)

Prothrombin complex concentrate (PCC) for the potential use in surgical settings with high risk of major bleeding.

RiaSTAP® Fibrinogen Concentrate (AFD)

Lyophilised fibrinogen for treatment of Acquired Fibrinogen Disease (AFD)

VMX-C001 rFX (FXa Inhibitor Bypass)*

Recombinant, modified, human coagulation Factor X, insensitive to inhibition by Factor Xa inhibitors, to restore coagulation in patients requiring urgent surgery/procedures while taking FXa inhibitors

Clazakizumab Anti-IL-6 mAb (MACE in ESKD)

Clazakizumab (an anti-IL6 antibody) for the prevention of cardiovascular morbidity and mortality in patients with end-stage kidney disease

Registration / Post Registration

HIZENTRA® (SCIg) 20% Liquid

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Primary Immunodeficiency (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency (SID)

PRIVIGEN® (IVIg) 10% Liquid

Intravenous 10% Immune Globulin (IVIg)(Plasma) for the treatment of Primary Immunodeficiency (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency (SID), Chronic Immune Thrombocytopenia (ITP)

ZEMAIRA®/RESPREEZA® Alpha 1 Antitrypsin (AAT Deficiency)

Human Alpha 1 Antitrypsin (AAT) (Plasma) for chronic augmentation and maintenance therapy in adults with A1-PI deficiency and emphysema

AFSTYLA® rFVIII (Hem A)

Recombinant factor VIII product for the treatment of adults and children with hemophilia A.

HEMGENIX® (Hem B)

Adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency).

IDELVION® rFIX-FP (Hem B)

Long-acting recombinant factor IX product for the treatment of hemophilia B.

FILSPARI®(Sparsentan) Dual ETA & AT1 antagonist (IgAN)

Oral, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) with high selectivity for the ETAR and AT1R for treatment of immunoglobulin A nephropathy (IgAN).

KORSUVA®/KAPRUVIA® KOR. agonist (CKD-aP)

Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with CKD in adult patients on hemodialysis.

RAYALDEE® Oral ext. release calcifediol (SHPT)

Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.

TAVNEOS® Oral C5a receptor inhibitor (AAV) †

Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).

VELTASSA® Oral potassium binder (HK)

A non-absorbed, oral potassium binder for the treatment of hyperkalemia.

ANDEMBRY® Anti-FXIIa mAb (HAE)

Subcutaneous humanised anti-factor XIIa monoclonal antibody for the treatment of Hereditary Angioedema (HAE).

FLUAD® Trivalent Adjuvanted Egg-based Influenza Vaccine

Egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) for protection against influenza A (H5N1) - the 'bird-flu' strain.

FLUCELVAX® Trivalent Cell-based Influenza Vaccine

For protection against seasonal influenza viruses in adults and children 6 months of age and older.

AUJEMFLU Trivalent Adjuvanted Cell-based Influenza Vaccine

Trivalent Seasonal Influenza Vaccine (Adjuvanted; Cell-based). High dose vaccine offering protection against different influenza virus strains.

*Co‑development project; partner owned asset with exclusive option rights held by CSL
† Market recalls planned

This pipeline is current as at 31st July 2026